全文获取类型
收费全文 | 280篇 |
免费 | 51篇 |
国内免费 | 2篇 |
专业分类
儿科学 | 4篇 |
基础医学 | 8篇 |
临床医学 | 19篇 |
内科学 | 146篇 |
皮肤病学 | 3篇 |
神经病学 | 4篇 |
外科学 | 7篇 |
综合类 | 5篇 |
药学 | 46篇 |
肿瘤学 | 91篇 |
出版年
2023年 | 9篇 |
2022年 | 5篇 |
2021年 | 6篇 |
2020年 | 17篇 |
2019年 | 20篇 |
2018年 | 19篇 |
2017年 | 27篇 |
2016年 | 12篇 |
2015年 | 23篇 |
2014年 | 23篇 |
2013年 | 66篇 |
2012年 | 24篇 |
2011年 | 24篇 |
2010年 | 15篇 |
2009年 | 17篇 |
2008年 | 11篇 |
2007年 | 10篇 |
2006年 | 3篇 |
2005年 | 2篇 |
排序方式: 共有333条查询结果,搜索用时 15 毫秒
11.
Flora Zagouri Evangelos Terpos Efstathios Kastritis Meletios-Athanasios Dimopoulos 《Expert opinion on pharmacotherapy》2015,16(12):1865-1877
Introduction: Lenalidomide, an immunomodulatory agent with unique mechanism of action, represents the cornerstone in the treatment of patients with multiple myeloma (MM) providing rapid and sustained control of the disease with a manageable safety profile.Areas covered: This review article, synthesizing all available data coming from trials and evaluating the efficacy and safety of lenalidomide in patients with MM, tries to provide to the clinicians with an easy-to-grasp synopsis of recent and clinically meaningful advances on the field.Expert opinion: Lenalidomide combined with dexamethasone is a safe and effective option for newly diagnosed MM patients ineligible for autologous stem cell transplantation (ASCT). Long-term administration of the agent as continuous treatment for ineligible for ASCT patients or maintenance therapy after ASCT has documented unprecedented progression-free survival improvements, whereas lenalidomide in combination with dexamethasone has shown deep and durable remissions for patients with relapsed and/or refractory disease. 相似文献
12.
Mateos MV García-Sanz R Colado E Olazábal J San-Miguel J 《British journal of haematology》2008,140(3):324-326
Lenalidomide combined with dexamethasone has significant clinical activity in the treatment of multiple myeloma (MM). In previous clinical trials lenalidomide-induced neutropenia was a frequent side-effect, often leading to treatment delays and dose reductions. We describe three MM patients treated with lenalidomide plus dexamethasone, which developed grade 3/4 neutropenia during the initial cycles, but without serious infection. Administration of granulocyte-colony stimulating factor (G-CSF) for 3 d prevented further neutropenia, treatment delays, dose reductions, or infectious complications during the following cycles. Consequently, G-CSF could be effective in preventing further neutropenia-related complications without compromising treatment efficacy in MM patients with lenalidomide-induced neutropenia. 相似文献
13.
14.
Dimopoulos MA Kastritis E Delimpasi S Katodritou E Hatzimichael E Kyrtsonis MC Repousis P Tsirogianni M Kartasis Z Parcharidou A Michael M Michalis E Tsatalas C Stefanoudaki E Hatjiharissi E Gika D Symeonidis A Terpos E Zervas K;Greek Myeloma Study Group 《European journal of haematology》2012,89(1):10-15
15.
虽然免疫抑制剂和蛋白酶体抑制剂的应用使多发性骨髓瘤治疗领域在过去10年取得了显著进展率最低的癌症之一。多发性骨髓瘤目前仍不可治愈,甚至连有效地维持缓解都极为困难。复杂的临床表现、比较研究数据的缺乏导致这一疾病的治疗变得更加复杂。但该疾病仍是预后差且5年存活多样的治疗选择以及长期、大规模受性方面均有显著提高,并且已通过加快审批通道进入市场,用于曾接受过多次既往治疗的患者,治疗复发性/难治性多发性骨髓瘤,但目前还未获得其完整的存活率数据。在基因组学领域,已开始对患者进行更加个体化的预后和治疗,然而这一领域还仅仅处于起步阶段。随着多发性骨髓瘤发生机制的进一步阐明以及竞争前研究合作的进一步加强,希望能够在这一治疗需求远远未被满足的领域快速研发出新—代靶向治疗药物。 相似文献
16.
Vera Adema Laura Palomo Andrea Toma Olivier Kosmider Francisco Fuster-Tormo Rocío Benito Rocío Salgado Esperanza Such María José Larrayoz Blanca Xicoy Jesus Maria Hernandez-Sanchez Paolo Maietta Alexander Neef Michaela Fontenay Mariam Ibañez Maria Diez-Campelo Sara Alvarez Jaroslaw P. Maciejewski Pierre Fenaux Francesc Sole 《British journal of haematology》2020,189(4):e133-e137
17.
Nishant Tageja Elisabet E. Manasanch Neha Korde Mary Kwok Sham Mailankody Manisha Bhutani Mark Roschewski Ola Landgren 《European journal of haematology》2014,92(1):1-12
Since smoldering multiple myeloma (SMM) was first described over three decades ago based on a case series of six patients, its definition and our understanding of the entity have evolved considerably. The risk of progression to symptomatic myeloma (MM) varies greatly among individuals diagnosed with myeloma precursor disease. Epidemiologic, molecular, flow cytometric and radiological techniques have demonstrated that this transformation to MM from precursor states is not sudden but rather a continuous overlapping series of events with evidence of end‐organ damage that could manifest in the earliest stages of disease. Contemporary antimyeloma therapies can yield rapid, deep, and durable responses with manageable toxicities, and molecular‐cell‐based measures are now available to rule out minimal residual disease. With this information, clinical studies with correlative measures can now be developed to test the fundamental hypothesis that intervention in early myeloma may provide a measurable clinical benefit to patients by either delaying progression or eradicating plasma cell clones. 相似文献
18.
19.
J. G. Gaultney MSc M. G. Franken MSc S. S. Tan PhD W. K. Redekop PhD P. C. Huijgens MD PhD P. Sonneveld MD PhD C. A. Uyl‐de Groot PhD 《Journal of clinical pharmacy and therapeutics》2013,38(1):41-47
What is known and objective: High costs of novel agents increasingly put pressure on limited healthcare budgets. Demonstration of their real‐world costs and cost‐effectiveness is often required for reimbursement. However, few published economic evaluations of novel agents for multiple myeloma exist. Moreover, existing cost analyses were heavily based on conventionally treated patients. We investigated real‐world health care costs of relapsed/refractory multiple myeloma in Dutch daily practice. Methods: A retrospective medical chart review was conducted for 139 patients treated between January 2001 and May 2009. Total monthly costs attributable to each cost component were described across all regimens and for bortezomib‐, thalidomide‐ and lenalidomide‐based treatment regimens. Results: Mean monthly total costs (€3,981) varied depending on the sequence of therapy (range: €442–€31,318). Significant cost drivers across all regimens included costs of therapy and hospital admissions. The acquisition costs for novel agents in particular accounted for 32% of mean total monthly costs. Prognostic factors associated with increased mean total monthly costs in multivariate regression analysis included low platelet counts (P = 0·01) and worsening performance status (P < 0·001). Mean total monthly costs of bortezomib‐ and lenalidomide‐based regimens were significantly higher than those for thalidomide‐based regimens in second, third and fourth treatment line. What is new and conclusions: Real‐world costs during treatment of relapsed/refractory multiple myeloma vary greatly. Cost drivers include hospital admissions and acquisition costs of novel agents. Costs also vary by prognostic factors and treatment‐related resource use. Future studies assessing the costs of combination therapy consisting of two or more novel agents are encouraged. 相似文献
20.